Changes for page Neurodiagnoses

Last modified by manuelmenendez on 2025/03/03 22:46
From version 4.5
edited by manuelmenendez
on 2025/01/27 23:00
Change comment: There is no comment for this version
To version 14.1
edited by manuelmenendez
on 2025/01/27 23:58
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -2,9 +2,10 @@
2 2  (((
3 3  (% class="container" %)
4 4  (((
5 -= Neurodiagnoses =
5 += //A new tridimensional diagnostic framework for CNS conditions// =
6 6  
7 -This project is focused on developing a novel nosological and diagnostic framework for neurological diseases. Using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies, we aim to create a structured, interpretable, and scalable diagnostic tool.
7 +This project is focused on developing a novel nosological and diagnostic framework for neurological diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
8 +We aim to create a structured, interpretable, and scalable diagnostic tool.
8 8  )))
9 9  )))
10 10  
... ... @@ -12,21 +12,70 @@
12 12  (((
13 13  (% class="col-xs-12 col-sm-8" %)
14 14  (((
15 -= What can I find here? =
16 += What is this about and what can I find here? =
16 16  
17 -* `/docs`: Documentation and contribution guidelines.
18 -* `/code`: Machine learning pipelines and scripts.
19 -* `/data`: Sample datasets for testing. - `/outputs`: Generated models, visualizations, and reports.
18 +== **Overview** ==
20 20  
21 -= Who has access? =
20 +The //Tridimensional Diagnostic Framework// redefines how neurodegenerative diseases (NDDs) are classified by focusing on:
22 22  
22 +* **Axis 1**: Etiology (genetic/sporadic and environmental factors).
23 +* **Axis 2**: Molecular Markers (biomarkers and proteinopathies).
24 +* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
25 +
26 +[[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]]
27 +
28 +This methodology enables:
29 +
30 +* Greater precision in diagnosis.
31 +* Integration of incomplete datasets using AI-driven probabilistic modeling.
32 +* Stratification of patients for personalized treatment.
33 +
34 +== **Diagnostic Axes** ==
35 +
36 +* (((
37 +**Axis 1: Etiology**
38 +
39 +* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers.
40 +* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression.
41 +* //Tests//: Genetic testing, lifestyle and cardiovascular screening.
42 +)))
43 +* (((
44 +**Axis 2: Molecular Markers**
45 +
46 +* //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression.
47 +* //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology.
48 +* //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET).
49 +)))
50 +* (((
51 +**Axis 3: Neuroanatomoclinical**
52 +
53 +* //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments.
54 +* //Examples//: Hippocampal atrophy correlating with memory deficits.
55 +* //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations.
56 +)))
57 +
58 +== **Applications** ==
59 +
60 +This system enhances:
61 +
62 +* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials.
63 +* **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
64 +
65 +== Who has access? ==
66 +
23 23  We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
24 24  
25 -== How to Contribute: ==
69 +== How to Contribute ==
26 26  
27 27  * Access the `/docs` folder for guidelines.
28 28  * Use `/code` for the latest AI pipelines.
29 29  * Share feedback and ideas in the wiki discussion pages.
74 +
75 +== Key Objectives ==
76 +
77 +* Develop interpretable AI models for diagnosis and progression tracking.
78 +* Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
79 +* Foster collaboration among neuroscientists, AI researchers, and clinicians.
30 30  )))
31 31  
32 32  
... ... @@ -36,11 +36,11 @@
36 36  {{toc/}}
37 37  {{/box}}
38 38  
39 -== Key Objectives: ==
89 +== Main contents ==
40 40  
41 -* Develop interpretable AI models for diagnosis and progression tracking.
42 -* Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
43 -* Foster collaboration among neuroscientists, AI researchers, and clinicians.
44 -
91 +* `/docs`: Documentation and contribution guidelines.
92 +* `/code`: Machine learning pipelines and scripts.
93 +* `/data`: Sample datasets for testing.
94 +* `/outputs`: Generated models, visualizations, and reports.
45 45  )))
46 46  )))
tridimensional.png
Author
... ... @@ -1,0 +1,1 @@
1 +XWiki.manuelmenendez
Size
... ... @@ -1,0 +1,1 @@
1 +149.8 KB
Content
Collaboratory.Apps.Collab.Code.CollabClass[0]
Public
... ... @@ -1,1 +1,1 @@
1 -No
1 +Yes
XWiki.XWikiRights[3]
Allow/Deny
... ... @@ -1,0 +1,1 @@
1 +Allow
Levels
... ... @@ -1,0 +1,1 @@
1 +view
Users
... ... @@ -1,0 +1,1 @@
1 +XWiki.XWikiGuest
XWiki.XWikiRights[4]
Allow/Deny
... ... @@ -1,0 +1,1 @@
1 +Allow
Groups
... ... @@ -1,0 +1,1 @@
1 +XWiki.XWikiAllGroup
Levels
... ... @@ -1,0 +1,1 @@
1 +view